King Luther Capital Management Corp increased its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 4.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 149,642 shares of the company's stock after buying an additional 6,484 shares during the quarter. King Luther Capital Management Corp's holdings in Eli Lilly and Company were worth $123,591,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in the stock. MSA Advisors LLC grew its position in Eli Lilly and Company by 212.5% during the first quarter. MSA Advisors LLC now owns 2,500 shares of the company's stock worth $2,065,000 after buying an additional 1,700 shares in the last quarter. Covington Investment Advisors Inc. boosted its holdings in shares of Eli Lilly and Company by 3.1% in the 1st quarter. Covington Investment Advisors Inc. now owns 21,285 shares of the company's stock valued at $17,579,000 after purchasing an additional 640 shares in the last quarter. Polen Capital Management LLC boosted its holdings in shares of Eli Lilly and Company by 35.4% in the 1st quarter. Polen Capital Management LLC now owns 1,754,571 shares of the company's stock valued at $1,449,118,000 after purchasing an additional 459,182 shares in the last quarter. Sierra Summit Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 6.6% in the 1st quarter. Sierra Summit Advisors LLC now owns 11,575 shares of the company's stock valued at $9,560,000 after purchasing an additional 719 shares in the last quarter. Finally, Fiduciary Family Office LLC boosted its holdings in shares of Eli Lilly and Company by 2,357.0% in the 1st quarter. Fiduciary Family Office LLC now owns 2,457 shares of the company's stock valued at $2,029,000 after purchasing an additional 2,357 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.
Insider Transactions at Eli Lilly and Company
In other Eli Lilly and Company news, Director Jamere Jackson acquired 200 shares of the stock in a transaction dated Friday, August 8th. The stock was purchased at an average cost of $639.56 per share, with a total value of $127,912.00. Following the transaction, the director owned 9,402 shares in the company, valued at approximately $6,013,143.12. The trade was a 2.17% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. 0.14% of the stock is currently owned by corporate insiders.
Eli Lilly and Company Trading Down 2.5%
NYSE:LLY traded down $15.71 during trading hours on Friday, hitting $625.15. 14,089,857 shares of the company were exchanged, compared to its average volume of 5,397,104. The stock has a market capitalization of $591.68 billion, a price-to-earnings ratio of 40.86, a price-to-earnings-growth ratio of 0.87 and a beta of 0.44. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a one year low of $623.78 and a one year high of $972.53. The company has a fifty day simple moving average of $774.10 and a 200 day simple moving average of $799.34.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%. Eli Lilly and Company's revenue for the quarter was up 37.6% compared to the same quarter last year. During the same period last year, the company earned $3.92 EPS. Sell-side analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.
Eli Lilly and Company Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's dividend payout ratio (DPR) is currently 48.82%.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on LLY. Leerink Partners reaffirmed a "market perform" rating and issued a $715.00 target price on shares of Eli Lilly and Company in a report on Thursday. Morgan Stanley reaffirmed an "overweight" rating and issued a $1,135.00 target price (up previously from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. UBS Group reduced their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a report on Friday. Hsbc Global Res downgraded Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. Finally, HSBC downgraded Eli Lilly and Company from a "buy" rating to a "reduce" rating and reduced their target price for the company from $1,150.00 to $700.00 in a report on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $984.41.
Get Our Latest Analysis on Eli Lilly and Company
Eli Lilly and Company Company Profile
(
Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Recommended Stories

Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report